<DOC>
	<DOC>NCT01502228</DOC>
	<brief_summary>Given the growing importance of anti-angiogenic therapies in the treatment of metastatic renal carcinoma, it is expected that this trial will establish the preliminary data needed to apply for funding of a larger clinical investigation of the potential role of PET perfusion imaging in management of renal carcinoma, and potentially other cancers.</brief_summary>
	<brief_title>PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<criteria>Ability to understand and willingness to sign a witnessed, informed consent and authorization for the release of health information. Patients with a diagnosis of relapsed Stage IV renal cell cancer that are medically unresponsive to prior treatment or surgically unresectable and with metastases that fall within the PET/CT fieldofview that can include the heart. Being considered for systemic therapy with Sunitinib Women who are pregnant, breastfeeding, or of childbearing potential and not using birth control Having no telephone or a reliable way in which study personal can contact them Subjects who are claustrophobic and cannot tolerate imaging procedures Subjects who weigh &gt; 350 lb. (upper weight limit of scanner beds)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>